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Critical subcellular targets of cisplatin and related platinum analogs in
rat renal proximal tubule cells. The clinical usefulness of chemotherapeu-
tic agents containing the platinum moiety is often limited by their
nephrotoxicity. To investigate the mechanism of nephrotoxicity, and to
assess the effects of platinum analogs on specific organdIes and basal
protein synthesis, biochemical and ultrastructural analyses were per-
formed in rat renal proximal tubule cells (RPTC5). Neutral red (NR)
uptake was used to measure lysosomal function, and conversion of MTT
to forrnazan used to assess mitochondrial function. Despite their differ-
ential toxicity, cisplatin, carboplatin and CI-973 caused similar progressive
inhibition of specific functions, suggesting they may share a common
mechanism of nephrotoxicity. Protein synthesis was the earliest indicator
of toxicity, followed by NR uptake and MTF conversion. Fluorescent
probes for lysosomes (acridine orange) and mitochondria (rhodamine
123) confirmed that cisplatin's toxicity to RPTCs was delayed and
cumulative. Condensation of nucleolar components and fragmentation of
RER were observed in RPTCs treated for as little as two hours. Since the
nucleolus is the site of ribosome biogenesis, the early inhibition of protein
synthesis by cisplatin may arise from disruption of this region. In contrast,
mitochondrial dysfunction and swelling were late-stage events, and are
therefore unlikely to be the primary targets of nephrotoxic platinum
compounds.
The intracellular targets of the chemotherapeutic agent cispla-
tin in renal proximal tubule cells (RPTCs) are of particular
interest in light of the drug's nephrotoxicity. Although the site of
damage by cisplatin and related analogs has been localized to the
S3 segment of the proximal tubule [1—31, the location of the initial
injury and the molecular cascade which leads ultimately to cell
death are unknown. In a series of elegant in vitro experiments,
Rosenberg and Sato [4] have demonstrated that cisplatin inter-
feres with the joining of the 48 S and 60 S ribosomal subunits by
binding, thereby preventing translation. Others [5, 6] have focused
on mitochondria as primary targets of cisplatin. The idea that
cisplatin specifically inhibits mitochondrial respiration has been
challenged by experiments describing enhanced mitochondrial
uptake of rhodamine 123 (an indicator of positive membrane
potential) by EL-4 lymphoma cells [7], and cisplatin-induced
inhibition of DNA, RNA and protein syntheses in the absence of
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mitochondrial dysfunction [8]. Lipid peroxidation has also been
implicated as the mechanism of cisplatin-induced nephrotoxicity
[6, 9], although cisplatin failed to induce oxidative damage in
kidney microsomes in vitro [10]. Because mitochondrial damage is
easily detected ultrastructurally and by biochemical manipulation
of isolated mitochondria, this organelle has been studied more
extensively than other cellular components. Lysosomes, acidic
compartments whose heterogeneous distribution intra- and inter-
cellularly makes them less amenable to study, are reported to
change in number following cisplatin exposure [11, 12].
To define the temporal relationship between the initiation of
lysosomal damage, mitochondrial damage and inhibition of pro-
tein synthesis, primary cultures of rat RPTCs were treated with
cisplatin, carboplatin and CI-973, and assessed over a 24-hour
period. Additional experiments were conducted to examine the
effect of short-term exposure to cisplatin on onset and develop-
ment of damage. Using biochemical and ultrastructural assays, we
demonstrate that the inhibition of mitochondrial function by
platinum compounds occurs subsequent to nucleolar disintegra-
tion, inhibition of protein synthesis and lysosomal damage.
Methods
Materials
Krebs-HEPES buffer was used for the perfusion of rat kidney
and consisted of: 132 mivi NaCl, 10 m sodium acetate, 4.8 msi
KC1, 1.2 mM KH2PO4, 2.5 mM CaC12, 1.2 mM MgSO4, and 13 mM
HEPES, pH 7.4. Iron oxide was prepared in Krebs-HEPES buffer
at a concentration of 4 mg/mI. Bio-Rad protein assay reagent
(Bio-Rad Laboratories, Richmond, CA, USA) was used to deter-
mine the protein concentration of suspensions of sonicated prox-
imal tubules according to the manufacturer's instructions. Basal
media plus deferoxamine consisted of Dulbecco's Modified Ea-
gle's Nutrient Mixture F-12 Ham (DME/F12 1:1 mixture) supple-
mented with 20 mt NaHCO3, 15 mivi HEPES, 0.1 mg/ml BSA, 66
xg/ml streptomycin sulfate, 30 jxg/ml penicillin G, and 33 xg/ml
deferoxamine, pH 7.4. Supplemented media contained 0.1 mg/ml
BSA, 10 ng/ml epidermal growth factor (Upstate Biotechnology
Inc., Lake Placid, NY, USA), 10 ng/ml cholera toxin, 5 xg/ml
human transferrin, 100 ng/ml hydrocortisone, 7.5 pg/ml triiodo-
thryonine and 10 j.tg/ml insulin. Collagenase shaking solution was
prepared as a 6 mg/mI BSA, 270 U/ml collagenase type II, 80
Lg/ml trypsin inhibitor, 70 U/ml DNAase I solution in basal media
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plus deferoxamine. All solutions were filter-sterilized prior to use.
Carboplatin [cis-diamine-1,1-cyclobutane dicarboxylate platinum
(II)] and CI-973 ([SP-4—3(R)]-[1,1-cyclobutanedicarboxylato
(2-)](2-methyl-1,4-butanediamine-N,N') platinum) were synthe-
sized by the Warner-Lambert Co. Cisplatin (cis-diamminedichlo-
roplatinum (II)) was purchased from Sigma Chemical Co. (St.
Louis, MO, USA). Cisplatin, carboplatin and CI-973 were dis-
solved in supplemented media for treatment of RPTCs. Neutral
red (NR) solution, MIT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphe-
nyl-tetrazolium bromide), acridine orange, rhodamine 123 and
propidium iodide were prepared fresh on the day of use in Hanks'
Balanced Salt Solution (HBSS) (Gibco BRL; Grand Island, NY,
USA). Except as noted, all reagents were purchased from Sigma
Chemical Co.
Isolation of RPTCs
Male Wistar rats (100 to 250 g) were anesthetized with xylazine/
ketamine and both kidneys then perfused via the abdominal aorta
with ice-cold, oxygenated Krebs-HEPES buffer followed by a 4
mg/mi solution of magnetic iron oxide. Kidneys were immediately
placed in ice-cold, oxygenated Krebs-HEPES buffer and decap-
sulated. The cortex was grossly dissected from the medulla which
was discarded. Isolation of proximal tubules was performed as
described by Hatzinger and Stevens [13]. Briefly, cortical tissue
was disrupted by 2 cycles of digestion in collagenase shaking
solution at 37°C and homogenization of tissue, poured over 253
pm mesh and the flow-through cleared of iron using a stir bar.
Distal and proximal tubules were gravity-separated twice on ice,
and the pellet containing proximal tubules was then resuspended
in basal media plus deferoxamine. Tubules were diluted in basal
media plus deferoxamine to a concentration of 110 to 120 .tg
protein/ml and plated in 12-well tissue clusters (Costar, Cam-
bridge, MA, USA) (Day 1). Sixteen hours later, media was
replaced with supplemented media plus 1% fetal bovine serum.
By electron microscopy, cells exhibited the brush border typical of
RPTCs and intercellular tight junctions characteristic of epithelial
cells. Lack of detectable hexokinase activity was used as an
indicator that contaminating distal tubules had been removed
from tubule suspension prior to plating [13]. Tubules were
cultured for four days in a 37°C incubator under 5% C02/95% air
and then treated (Day 5) with cisplatin, carboplatin or CI-973
when cells were approximately 70% confluent. Supplemented
media plus 1% fetal bovine serum was replaced every two days.
Neutral red assay
RPTCs were treated with cisplatin, carboplatin or CI-973 in
supplemented media (no serum was present during treatment) for
24 hours and then assayed for NR uptake performed as described
[14]. Cell cultures were incubated for three hours with NR (final
concentration 66 g/ml) to permit uptake. The NR solution was
decanted following uptake and cells then fixed for 30 to 60
seconds in 1% formaldehyde/1% CaCI2. NR was extracted from
cells with 1% acetic acid/50% ethanol, and the optical density was
measured in a Biotek microtiter plate reader (Winooski, VT,
USA) at 540 nm. Results are expressed as a percentage of vehicle
control NR uptake. Alternately, RPTCs were treated with cispla-
tin (10 or 100 LM) or supplemented media for 0, 0.5, 1, 2, 6 or 24
hours of a 24-hour experiment. Treatment media was replaced
with supplemented media after various treatment times and the
NR assay performed 24 hours following the start of the experi-
ment.
MTT conversion to formazan
To measure mitochondrial function after a 24-hour treatment
with cisplatin, carboplatin or CI-973, RPTCs were incubated three
hours at 37°C in a 0.5 mg/ml solution of MIT (in HBSS). MIT
solution was aspirated from cells, the formazan product was
extracted with DMSO, and absorbance of samples at 540 nm was
measured using a Biotek microtiter plate reader. Results are
expressed as a percent of the absorbance of dye from control
wells.
Platinum content
Following drug treatment, cells were trypsinized for 10 minutes
and gently scraped from the bottom of six-well tissue culture
plates with a rubber policeman. Cells were washed twice in HBSS,
sonicated and a sample taken for measurement of total protein.
An equal volume of concentrated HNO3 was added to sonicate.
Platinum concentrations were measured by flameless atomic
absorption spectrophotometry (using a Perkin Elmer 4100 ZL
atomic absorption spectrophotometer with Zeeman correction
and hollow cathode platinum lamp) and corrected for dilution in
HNO
Protein synthesis
Protein synthesis was measured by the incorporation of 3H-
leucine into RPTCs. Cells were incubated in the presence or
absence of drug in media containing 0.3 Ci/ml 3H-leucine for 6
or 24 hours. To measure the effect of short-term incubations on
protein synthesis, RPTCs were incubated for 0, 0.5, 1, 2, 6 or 24
hours in drug containing 0.3 Ci/ml 3H-leucine. Treatment media
was replaced with supplemented media containing 0.3 pCi/ml
3H-leucine after specified incubation times for the balance of the
24-hour experiment. At the conclusion of the experiment, cells
were washed once with HBSS, fixed in methanol and air-dried for
15 minutes. Cellular proteins were precipitated in three washes of
ice-cold 10% trichloroacetic acid. Wells were washed in methanol
and air-dried, and 0.5 ml 0.5 N NaOH added to each well to
solubilize acid-precipitable proteins. Samples were collected in
scintillation vials and counted using a Beckman LS 6500 scintil-
lation counter.
Fluorescence microscopy
Organelle-specific dyes were used to qualitatively assess the
effect of cisplatin on RPTC function. Acridine orange was used as
a marker of lysosomal function. Rhodamine 123 which reflects
membrane potential was used as a marker of mitochondrial
function. Cells were treated for 0, 2, 4 or 6 hours with 100 M
cisplatin and then incubated in supplemented media for the
balance of the 24-hour experiment. Following the treatment
period, cells were incubated with prewarmed acridine orange (1
ELM) or rhodamine 123 (10 .tg/ml) for 30 minutes at 37°C. Cells
were washed twice with warm HBSS. Cells stained with rhoda-
mine 123 were further incubated in HBSS containing propidium
iodide (20 g/ml) (which detects non-viable cells) and cells
stained with acridine orange were incubated in HBSS only; cells
were examined immediately by fluorescence microscopy. A BDS
multimode microscope (Biological Detection Systems, Inc., Pitts-
burgh, PA, USA) with rhodamine and FITC filter sets (Chroma
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Fig. 1. Effect of platinum compounds on ) NR uptake and mitochondrial
conversion of MiT (fl) to formazan. RPTCs were treated with cisplatin
(A), carboplatin (B), or CI-973 (C) for 24 hours and then assayed for NR
uptake or MiT conversion (MTF). Data are expressed as the mean SE
relative to concurrent controls assigned a value of 100%. Significantly
different from control, P < 0.05.
0
Fig. 2. Platinum concentration following treatment with platinum com-
pounds. RPTCs were exposed to 100 I.LM cisplatin (CIS), 1 msi carboplatin
(CARB) or 1 mM CI-973 for 24 hours and then assayed for total cellular
platinum. The platinum concentrations (mean SE) in control cells was 3
3 nglmg protein. Significant difference between CIS-treated and
CARB- or CI-973-treated cells, P < 0.05.
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Fig. 3. Effect of treatment time on the development of toxicity in RPTCs.
Symbols are: (0)10 jIM; (•) 100 j.tM cisplatin. Cells were treated with
cisplatin for 0 to 24 hours, and then incubated in control media for the
balance of the 24-hour treatment period. Lysosomal function was assessed
with the NR assay. Data are expressed as mean su relative to control
cells assigned a value of 100%. Significant difference between cisplatin-
treated and concurrent control cells, P < 0.05.
Technology Corp., Brattleboro, VT, USA) was used for fluores-
cence microscopy. A cooled CCD camera (Model CH250, Pho-
tometrics, Tuscon, AZ, USA) was used to record the differential
fluorescence of acridine orange, rhodamine 123 and propidium
iodide as 12-bit, 512 X 512 pixel images. Images were processed
on a Macintosh Quadra 950 computer (Apple Computers, Inc.,
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Fig. 4. Protein synthesis is differentially-inhibited by platinum compounds.
RPTCs were treated with cisplatin (A.), carboplatin (B.) or CI-973 (C.) for
6 or 24 hours and then assayed for the incorporation of 3H-leucine into
acid-precipitable protein. Symbols are: (LII) control; () 10 /LM; () 100
tM; () 1 m. Results are expressed as mean SE relative to control cells
assigned a value of 100%. *signiflcant difference between treated cells and
concurrent controls, P < 0.05.
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Fig. 5. Inhibition of protein synthesis by cisplatin is dependent on the
exposure time. Symbols are: (0)10/sM; (•) 100 jsM cisplatin. RPTCs were
treated with cisplatin for 0, 0.5, 1, 2, 6, or 24 hours and then incubated in
control media for the balance of time remaining in the 24-hour treatment
period. Cells were then assayed for the incorporation of 3H-leucine into
acid-precipitable proteins. Results are expressed as mean SE relative to
control cells assigned a value of 100%. *Significant difference between
treated cells and concurrent control cells, P < 0.05.
Cupertino, CA, USA) using BDS-Image and Adobe Photoshop
software (Adobe Systems, Inc., Mountain View, CA, USA).
Electron microscopy
RPTCs were treated with control media or 100 p.M cisplatin for
0, 2, or 6 hours. In addition, a 24-hour experiment was done in
which cells were exposed to cisplatin for 2, 6 or 24 hours; cells
exposed for 2 or 6 hours were maintained in control media for the
balance of the 24 hour period. Cells maintained in culture media
without cisplatin for the specified time periods served as concur-
rent controls. At the end of the specified time intervals, cells were
fixed in 2.5% glutaraldehyde for 30 minutes, postfixed in 1%
osmium tetroxide for 30 minutes, and dehydrated in graded
ethanols. Cells were embedded by adding epon araldite to the
culture dishes. Beem capsule molds were inverted into the
epon-loaded wells to facilitate cell removal and sectioning follow-
ing polymerization. Blocks were sectioned at approximately 79 nm
and stained with 3% uranyl acetate and 5% lead citrate. Sections
were examined and photographed using a Hitachi H-600 electron
microscope.
Statistical analysis
Experimental data were obtained from at least three individual
experiments which were performed in triplicate. Results were
expressed as means SE. Data were analyzed by one-way analysis
of variance with comparisons of individual groups made by the
Bonferroni procedure. Differences between the means of experi-
mental and control groups were considered significant at a level of
P < 0.05.
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Fig. 6. Fluorescence microscopy of rat RPTCs treated with cisplatin. Cells were treated with 100 .tM cisplatin for the times indicated and then incubated
in control media for the balance of the 24-hour experimental period when they were assessed for acridine orange and rhodamine 123 uptake. Orange
fluorescence: uptake of acridine orange. Green fluorescence: uptake of rhodamine 123 by mitochondria contrasts with propidium iodide-staining (red)
of the nuclei of non-viable cells. Publication of this figure in color was made possible by Parke-Davis Pharmaceutical Research, a division of
Warner-Lambert Co.
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Fig. 7. Disruption of nucleoli (n) and RER accompany cisplatin treatment of rat RPTCs. (A) Control cells. The RER is continuous and studded with
ribosomes (inset, arrowheads). (B) Two-hour cisplatin treatment. The nucleoli show condensation and segregation of fibrillar and granular components
(n) and there is loss of ribosomes from and fragmentation of RER (arrowhead). Brush border characteristic of RPTCs can be seen (arrow). (C) Six-hour
cisplatin treatment. Nucleolar disintegration (arrows) accompanies fragmentation of RER (inset; arrowheads). Bars = 2 rm.
Results
Biochemical indicators of toxicity are differentially inhibited by
platinum compounds
NR uptake by lysosomes was an earlier indicator of the toxicity
of cisplatin, carboplatin and CI-973 than the mitochondrial con-
version of MTTto formazan (Fig. 1). Cisplatin was at least tenfold
more nephrotoxic than carboplatin or CI-973, inhibiting NR
uptake 33% at a concentration (10 .tM) at which neither carbo-
platin nor CI-973 had a significant effect. Ten ItM cisplatin, 1 mM
carboplatin and 100 .rM CI-973 inhibited lysosome function before
significantly decreasing mitochondrial function (Fig. 1). MIT
conversion was diminished by exposure of RPTCs to 100 LM
cisplatin or 1 mti CI-973 for 24 hours; carboplatin did not
significantly reduce MITconversion at any of the concentrations
studied. One hundred .tM cisplatin, which demonstrated signifi-
cant nephrotoxic potential at 24 hours did not significantly reduce
MIT metabolism or NR uptake after six hours (data not shown).
The relative toxicities of these platinum anticancer agents was
determined to be: cisplatin > CI-973 > carboplatin. Platinum
concentrations in RPTCs appeared to parallel drug concentration
since cells treated with 1 mi carboplatin and CI-973 accumulated
approximately twice the level of platinum as cells treated with 100
j.M cisplatin (Fig. 2).
Lysosome function is reduced by short treatments with cisplatin
To determine the minimum treatment time necessary to inhibit
lysosomal function, RPTCs were treated with cisplatin for be-
tween 0.5 and 24 hours and incubated with control media for the
balance of the 24-hour experimental period. Figure 3 demon-
strates that exposure of RPTCs to 100 .rM cisplatin for as little as
0.5 hours significantly inhibited uptake of NR at 24 hours.
Furthermore, the 60% decrease in lysosomal function detected
after continuous exposure to 100 jtM cisplatin for 24 hours (Fig. 1
and 3) was also evident in cells treated for only 6 of the 24 hour
period (Fig. 3), implying that full expression of cisplatin's cyto-
toxicity is delayed and cumulative. RPTCs treated with cisplatin
for 0.5 to 24 hours and then assayed for their ability to convert
MIT to formazan demonstrated that exposure to 100 .tM cisplatin
for six hours of a 24 hour experiment inhibited MIT conversion
by 40%, as effectively as a continuous 24-hour exposure (results
not shown). There was no significant difference in inhibition of
MIT conversion by 10 !.LM compared to 100 M cisplatin at 24
hours.
Protein synthesis is inhibited by platinum compounds
Total protein synthesis in RPTCs was differentially inhibited by
cisplatin, carboplatin and CI-973. Cisplatin was the most nephro-
toxic analog tested; concentrations as low as 10 iM reduced
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protein synthesis by 50% relative to control (6 hr; Fig. 4). In
contrast, a comparatively higher concentration of CI-973 (1 mM)
was needed to reduce protein synthesis by 25%. Significant
inhibition of protein synthesis by carboplatin was observed only
following 24 hours (Fig. 4). To further investigate the effect of
incubation time on the development of cisplatin toxicity, RPTCs
were incubated with cisplatin for 0 to 6 hours of a 24 hour period.
A 40% decrease in protein synthesis occurred in cells treated with
100 fLM cisplatin for as little as one hour of the 24-hour experi-
mental period (Fig. 5); this was similar to the rapid loss of
lysosomal function measured with the NR assay (Fig. 3). Treat-
ment of RPTCs with 10 M cisplatin for 6 of 24 hours also reduced
protein synthesis (Fig. 5). There was no significant difference in
inhibition of protein synthesis in cells treated with 100 LM
cisplatin for only 6 of 24 hours compared with those incubated in
cisplatin for 24 hours (Fig. 5). RPTCs treated with cisplatin for
only six hours showed less inhibition of protein synthesis (65%
decrease; Fig. 4) than those treated for six hours and incubated a
further 18 hours in control media (82% decrease; Fig. 5).
Morphological and functional changes in organelles reflect the
toxicity of cisplatin
Since the NR assay suggested that changes in lysosome bio-
chemistry occur within 23 hours following a one hour incubation
in 100 ILM cisplatin, changes to lysosomal function were investi-
gated using uptake of the fluorescent dye, acridine orange. This
was compared temporally to rhodamine 123 (green) fluorescence
in functioning mitochondria. In control cells, acridine orange
fluorescence was distributed in a punctate fashion and showed
heterogeneous intensity intra- and intercellularly (Fig. 6; Acri-
dine). Acridine orange fluorescence was also evident in the
nucleoli of control cells. Green fluorescence (indicating mainte-
nance of mitochondrial membrane potential) was localized to the
perinuclear region in control cells while the DNA of non-viable
cells stained red with propidium iodide (Fig. 6; Rhodamine).
Following a two hour treatment with 100 LM cisplatin, acridine
orange fluorescence was generally less intense and more diffuse,
and there were larger numbers of cells without nucleolar staining
and with predominantly perinuclear distribution of dye. These
changes (decreased nucleolar staining and fluorescence intensity)
were enhanced with 4 and 6 hour incubations in cisplatin. In
addition, RPTCs treated with cisplatin for 6 of 24 hours showed
cytoplasmic swelling and rounding relative to untreated controls.
As with acridine orange, the intercellular intensity of rhodamine
123 fluorescence in control cells was heterogeneous, although
comparatively more homogeneous within individual cells (Fig. 6;
Rhodamine). After treatment with cisplatin, rhodamine 123 flu-
orescence became more diffuse and the number of non-viable
cells detected with propidium iodide increased. After incubation
for six hours of a 24 hour period, rhodamine 123 was cytoplasmi-
cally restricted in some cells and numerous vacuoles could be seen
in other cells. Some treated cells were more fluorescent than
corresponding controls in the presence of rhodamine 123.
Ultrastructural evaluation of RPTCs treated for 2 or 6 hours
and then maintained in culture until 24 hours revealed cytoplas-
mic swelling, loss of cytoplasm, nuclear invagination and cytolysis
(examples not shown). Cells treated with cisplatin for the entire 24
hour period could not be evaluated due to extensive lysis and cell
loss. To identify early ultrastructural changes associated with 100
LM cisplatin exposure, additional cells were fixed immediately at
two and six hour timepoints. In these cells, obvious nucleolar
changes and loss of RER were identified (Fig. 7). Following the
two hour treatment, there was obvious nucleolar condensation,
and separation of granular and fibrillar components in RPTCs.
Additionally, RER was reduced and fragmented remnants ap-
peared to have lost ribosomes (Fig. 7b; arrowhead). However,
cells showing these changes still displayed the brush border
characteristic of RPTCs (Fig. 7b; arrow). At six hours, the
granular and fibrillar nucleolar components were segregated and
in the majority of cells nucleolar fragmentation was evident (Fig.
7c; arrows). Only small fragments of RER could be found
following six hours of cisplatin treatment (Fig. 7c; inset, arrow-
heads). At both two and six hours, there were no obvious changes
in other nuclear components and mitochondria appeared rela-
tively normal.
Discussion
RPTCs appear exquisitely sensitive to the damaging effects of
chemotherapeutic platinum compounds [2, 15]. However, the
mechanism by which cisplatin and its related analogs, carboplatin
and CI-973, induce cytotoxicity has yet to be determined. In this
study, we investigated the primary subcellular targets of cisplatin
by correlating morphological changes in organelles with corre-
sponding functional inhibition.
The relative toxicity of the three platinum compounds was
shown by different functional parameters to be: cisplatin > CI-973
> carboplatin. The relative toxicity of these compounds agrees
with previous reports in vivo [16] and in renal cortical slices in vitro
[17]. Toxicity developed in a time- and concentration-dependent
manner. Interestingly, despite differences in their relative neph-
rotoxicities, progression of specific functional inhibition occurred
similarly with cisplatin, carboplatin and CI-973. Treatment with
all platinum drugs inhibited protein synthesis and lysosomal
function, before decreasing mitochondrial function. This suggests
that these platinum compounds may share a common mechanism
for perturbing cell metabolism despite differences in their neph-
rotoxic potency.
Although cellular platinum levels were related to drug concen-
tration, platinum was an unreliable indicator of toxicity in rat
RPTCs. For example, cells treated with 1 mvt carboplatin or
CI-973 accumulated twice the level of platinum as those treated
with 100 .tM cisplatin, but in general caused less inhibition of
protein synthesis, NR uptake and mitochondrial conversion of
MiT. Although some have reported that rabbit RPTCs accumu-
lated more platinum in the presence of cisplatin than carboplatin
[18], researchers have commonly reported that transplatin treat-
ment, which is non-nephrotoxic in vivo [19], leads to high cellular
accumulation of platinum [17—20]. Therefore, the hypothesis that
platinum compounds which cause the highest cellular accumula-
tion of platinum are also the most nephrotoxic may be too
simplistic; instead it is possible that differential nephrotoxicity
depends upon the interaction of individual drugs with specific
intracellular components.
In the present study, mitochondria were less sensitive to the
effects of platinum compounds than lysosomes or protein synthe-
sis. In fact, some RPTCs appeared more fluorescent in the
presence of rhodamine 123 following cisplatin treatment than
controls. Rhodamine 123 fluorescence was also enhanced in EL-4
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lymphoma cells treated with cisplatin, possibly due to mitochon-
drial biogenesis in the absence of cell division [7]. In rabbit RPTCs
the mitoehondrial enzyme, suecinic dehydrogenase, was not af-
fected by 24 hour treatment with a comparable concentration of
cisplatin [8]. However, other reports on isolated mitochondria [6]
and suspensions of rabbit renal proximal tubules [5] have sug-
gested that damage to these organelles constitutes cisplatin's
primary mechanism of action. These studies differ from ours and
those of others [81 in one major respect: the concentrations of
cisplatin used were 10 to 20 times greater than the highest
concentration used in our study. As a result, mitochondrial
changes which appeared after the 24-hour cisplatin treatment in
our rat RPTCs were reported within two hours. Choie, Del
Campo and Guarino [21] reported that platinum levels were low
in the renal mitochondria of cisplatin-treated rats, and that the
highest levels were found in the nuclei and microsomes. We
suggest that mitochondria may not be the initial targets of
cisplatin but may exhibit damage in association with general loss
of viability.
Because of the apparently greater sensitivity of protein synthe-
sis and lysosomal function to inhibition by platinum compounds,
and because in patients a single dose of cisplatin is routinely given
per cycle, we examined the effect of short-term cisplatin exposure
on RPTC function at later timepoints. Experiments in which
analyses of functional viability were delayed to 24 hours (after
cisplatin treatment for up to 6 hr) demonstrated that damage to
protein synthetic machinery and lysosome function was delayed
and cumulative. Although a 6 hour exposure to 100 jIM cisplatin
had no effect on the function of lysosomes in RPTCs (results not
shown), 18 hours following a six hour treatment the same cells
showed a 60% loss of function. Fluorescence microscopy using
acridine orange, which accumulates preferentially in lysosomes
because of their low pH and does not intercalate into the DNA of
viable cells [22], confirmed the gradual and uniform loss of
lysosomal function with increased time of exposure to cisplatin.
Since platinum complexes have been reported to limit lysosomal
protein degradation [23], they may also interfere with mainte-
nance of low lysosomal pH.
The inhibition of protein synthesis in a kidney cell line, LLC-
PK1 [24], primary rabbit RPTCs [8, 18] and rat RPTCs (this study)
may be explained by cisplatin's ability to decrease ribosome
assembly in vitro by interfering with the joining of the 48 S and 60
S subunits [4]. Because protein synthesis was inhibited in the
absence of significant defects in mitochondrial function, we agree
with others [8, 24] that protein synthesis is a critical target for
cisplatin, and further suggest that carboplatin and CI-973 may
decrease the viability of rat RPTCs in a similar manner.
To further examine the possibility that inhibition of protein
synthesis was the initiating factor in cisplatin-induced nephrotox-
icity, intracellular components of rat RPTCs were examined by
electron microscopy after two or six hours. At these time-points,
negative effects on functional parameters were minimal. The most
striking and rapid alteration observed was the segregation of
fibrillar and granular components of the nucleolus, margination of
the nucleolus, and its eventual disintegration. These changes
occurred in >80% of the cells examined. To our knowledge, this
phenomenon has not been described previously in vitro; however,
nucleolar segregation has been reported in neurons [25] and
kidneys [3] of eisplatin-treated rats. Since the nucleolus is the
primary site of ribosome biogenesis [26] and cisplatin inhibits this
biogenesis in vitro [4], interference with nucleolar structure or
function might decrease ribosome number and, ultimately, pro-
tein synthesis. Degranulation of the RER occurred within two
hours of treatment, and by six hours RER was present only as
small fragments. In light of these intracellular changes, it is hardly
surprising that 100 gM cisplatin caused a 60% reduction in protein
synthesis at six hours. Because of their relevance to protein
synthesis and cellular homeostasis, we conclude that morpholog-
ical alterations to the nucleolus and RER, coupled with inhibition
of lysosomal function, may be critical central events in the
expression of eisplatin's nephrotoxicity.
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